Leiviskä Jaana, Sundvall Jouko, Jauhiainen Matti, Laatikainen Tiina
THL, Kansantautien ehkäisyn osato, tautiriskiyksikkö.
Duodecim. 2014;130(22-23):2331-7.
Laboratory diagnostics of dyslipidemia has been based on serum total cholesterol, HDL- cholesterol, triglycerides, and calculated or direct LDL-cholesterol measurements. Apolipoprotein A-I (apoA-I) is the main protein in HDL particles, and apoB is the main protein in all other atherogenic lipoprotein particles. An increased number of apoB-containing lipoproteins with normal total and LDL-cholesterol is a common feature associated with obesity, metabolic syndrome, or type 2 diabetes. If the risk assessment of cardiovascular disease in these cardiometabolic disturbances is primarily based on LDL-cholesterol levels, the actual risk may be underestimated. Instead of cholesterol measurements, ApoA-Iand apoB measurements could produce more specific information on dyslipidemia.
血脂异常的实验室诊断一直基于血清总胆固醇、高密度脂蛋白胆固醇、甘油三酯以及计算得出的或直接测量的低密度脂蛋白胆固醇。载脂蛋白A-I（apoA-I）是高密度脂蛋白颗粒中的主要蛋白质，而apoB是所有其他致动脉粥样硬化脂蛋白颗粒中的主要蛋白质。总胆固醇和低密度脂蛋白胆固醇正常但含apoB的脂蛋白数量增加是肥胖、代谢综合征或2型糖尿病的常见特征。如果在这些心脏代谢紊乱中对心血管疾病的风险评估主要基于低密度脂蛋白胆固醇水平，实际风险可能会被低估。与胆固醇测量不同，apoA-I和apoB测量可能会提供有关血脂异常更具体的信息。
